Core Insights - Protagonist Therapeutics (PTGX) shares have increased nearly 7% following the FDA approval of icotrokinra, developed in partnership with Johnson & Johnson (JNJ), for treating moderate-to-severe plaque psoriasis in patients aged 12 and older [1][6] FDA Approval and Product Details - Icotrokinra, marketed as Icotyde in the U.S., is the first targeted oral peptide designed to inhibit the IL-23 receptor [2][4] - The FDA approval was supported by data from four phase III studies within the ICONIC program, demonstrating significant skin clearance and a favorable safety profile [4] Financial Implications - Protagonist will receive a $50 million milestone payment from JNJ, with potential for up to $580 million more in regulatory and sales-based milestones [6][7] - Protagonist is entitled to tiered royalties on global net sales, ranging from 6% to 10%, with an average of approximately 7.25% at $4 billion in annual sales [7] Market Potential - JNJ believes Icotyde has the potential to revolutionize plaque psoriasis treatment as a once-daily oral alternative to existing injectables [8] - Icotyde is also being evaluated for other indications, including psoriatic arthritis and inflammatory bowel diseases, indicating broader market potential [9]

This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8]

Core Insights - Johnson & Johnson (JNJ) has made significant advancements in its pipeline, achieving key clinical and regulatory milestones that are expected to drive growth through the latter half of the decade [1] - The company received approvals for new products, including Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis [1] Product Approvals and Pipeline - Inlexzoh is a novel drug-releasing system that allows for sustained local delivery of cancer treatment directly into the bladder [2] - Nipocalimab, an FcRn blocker, is under review for multiple immune-mediated conditions, including warm autoimmune hemolytic anemia and systemic lupus erythematosus, with potential for significant market impact [2] - In 2026, J&J and Protagonist Therapeutics received FDA approval for icotrokinra (marketed as Icotyde), an oral targeted peptide inhibitor for moderate-to-severe plaque psoriasis [3][10] - Icotyde's approval was based on data from four phase III studies, demonstrating significant skin clearance and a favorable safety profile [4] - Icotyde is expected to revolutionize plaque psoriasis treatment by offering a once-daily oral option, contrasting with existing injectable treatments [5][6] Market Potential - J&J anticipates that Inlexzoh, Icotyde, and Imaavy are among ten new drugs that could collectively achieve peak sales of $5 billion [7] - The company expects a more pronounced impact from new products in 2026 compared to 2025, highlighting the strength of its late-stage pipeline [8] Financial Performance - JNJ's shares have outperformed the industry, rising 45.6% over the past year compared to an 8.0% increase in the industry [9] - The company's shares currently trade at a price/earnings ratio of 20.23, higher than the industry average of 17.25, indicating a slightly expensive valuation [11] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.46 to $11.54, while the estimate for 2027 has risen from $12.25 to $12.44 [12]

Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s latest stock calls as he shared how to navigate Wednesday’s tough tape. Cramer believes that the stock should have gone higher, as he stated: What can you do on days like today? Well, the investing club… We like to buy, not big, but we’re not sellers. Why? Couple of reasons. We now think that Iran’s response could be more anemic than its previous barrage of pain. We’re going to find out soon enough though. We also like the stock market… when it’s oversol ...

Market Overview - The overall market is facing consistent pressure, primarily due to higher-than-expected inflation data and adjustments in the labor market [2][3] - The short end of the yield curve has seen significant increases, particularly the 2-year yield, indicating a shift in market sentiment regarding Federal Reserve actions [2][3] - Geopolitical tensions, especially in the Middle East, are contributing to market uncertainty, particularly affecting energy and shipping sectors [3] Oracle - Oracle's stock has seen a significant pullback of approximately 21% year-to-date and a 55% decline from its recent highs following earnings reports [5][6] - There is a belief that Oracle may have temporarily bottomed, with support levels around $155 to $160, suggesting potential for upside if market stability is achieved [7][8] - Technical analysis indicates a bearish trend, with caution advised despite signs of a possible short-term bottom [10][12] Johnson & Johnson - Johnson & Johnson has performed relatively well, up about 14% this year, despite a 6% pullback from recent highs [19][20] - The stock is viewed as defensive, with a potential for building off current levels, and a risk reversal strategy is suggested to capture further upside [18][19] - Technical indicators show a constructive chart, but there are concerns about weakening price momentum and potential breakdowns below key support levels [22][24] Starbucks - Starbucks has been the strongest performer this year, but there are mixed opinions regarding its costly turnaround strategy [25][27] - The stock is currently positioned for potential downside, with a strategy to buy puts to capture further weakness while having the opportunity to acquire shares at lower levels [28][31] - Technical analysis indicates defined resistance around $100 to $104 and support near $80, with recent trading behavior resembling that of a utility stock rather than a growth company [33][34]

Core Viewpoint - Glencore's South African ferrochrome unit is considering withdrawing from negotiations with the government regarding a discounted electricity package due to perceived unfavorable conditions [1] Group 1: Company Insights - The executive from Glencore indicated that the current terms of the electricity package are not satisfactory for the company [1] - The potential withdrawal from talks highlights the challenges faced by the ferrochrome unit in securing favorable operational conditions [1] Group 2: Industry Context - The situation reflects broader issues within the South African energy sector, where companies are seeking more favorable terms to ensure competitiveness [1] - The outcome of these negotiations could have significant implications for the ferrochrome industry in South Africa, particularly in terms of operational costs and profitability [1]

Key Takeaways AbbVie shares dropped 5.2% as J&J secured FDA approval for Icotyde in plaque psoriasis.Skyrizi, AbbVie's top drug, posted $17.6B sales in 2025 and is key to post-Humira growth.Icotyde's oral delivery and expanding indications may intensify IL-23 competition over time.Shares of AbbVie (ABBV) fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as investors grow wary of Johnson & Johnson’s (JNJ) newly approved immunology therapy, Icotyde, which could emerg ...

According to the now well publicized MIT-affiliated research and reporting, fewer than 5% of enterprise AI pilots ever deliver measurable business value. The other 95%? They’re still stuck in what we call AI Purgatory: exciting demos, scattered pilots, and vanishing trust.For the past couple of years, corporate leaders have been sprinting into the AI era with a mixture of urgency and anxiety. Boards are calling. Investors are asking. Competitors are announcing. And CIOs, under immense pressure, have respond ...

Core Viewpoint - Johnson & Johnson (J&J) has transitioned by spinning off its consumer health business to focus on innovative medicine and medtech, despite facing challenges from the loss of exclusivity of its top-selling drug, Stelara [1][2] Group 1: Company Performance - J&J has shown resilience by managing growth in its two main businesses despite the decline of Stelara [2] - The company's shares have increased by 15% this year, contrasting with the S&P 500's decline, indicating strong performance during uncertain market conditions [4] - J&J has 28 platforms or products generating at least $1 billion annually, allowing it to move past the Stelara exclusivity loss [5] Group 2: Financial Metrics - J&J's market capitalization is $572 billion, with a current share price range between $235.50 and $239.11 [6] - The company has a gross margin of 67.97% and a dividend yield of 2.19% [6] Group 3: Dividend Growth - J&J is recognized as a Dividend King, having increased its dividend for over 50 years, demonstrating a commitment to shareholder returns [7] - The company pays a dividend of $5.20, which is higher than the S&P 500's dividend yield of 1.1%, making it an attractive option for passive income [9]